Physician profile
Tracy Romans
NPI 1023466786
$1,139.58
in general payments reported to CMS, 2019-2025
13 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.59 · 2022: $497 · 2023: $332 · 2024: $92.47 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.47 |
| Education | $105.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $324.77 | 2021-2025 | Jakafi |
| Janssen Biotech, INC. | $224.09 | 2023-2024 | Erleada, Akeega, Rybrevant |
| Lilly USA, LLC | $124.79 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Gilead Sciences, INC. | $99.98 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $75.68 | 2022 | |
| Janssen Scientific Affairs, LLC | $62.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $61.90 | 2023 | |
| Genentech USA, INC. | $52.45 | 2022 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Lynparza |
| Seagen INC. | $25.18 | 2023 | Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $24.14 | 2025 | Ninlaro |
| Astrazeneca Pharmaceuticals LP | $19.34 | 2023 | Lynparza |
| Caris Mpi, INC. | $18.98 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Romans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.